Additional file 2: Table S2. of The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Hiroaki Sugiura (190855); Hiroshi Fujiwara (236227); Ho Namkoong (3551780); Kazuma Yagi (3551795); Makoto Ishii (229384); Naoki Hasegawa (1698301); Osamu Iketani (4346008); Sadatomo Tasaka (729727); Shoji Suzuki (1424941); Takahiro Asami (325491); Takanori Asakura (3551786); Tetsuro Kamo (4346002); Tomoko Betsuyaku (87406); Tomoyasu Nishimura (3551777); Yohei Funatsu (4346005); Yoshifumi Uwamino (4345999); Yoshitake Yamada (3551792)

Additional file 2: Table S2. of The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Authors: Hiroaki Sugiura (190855)
Hiroshi Fujiwara (236227)
Ho Namkoong (3551780)
Kazuma Yagi (3551795)
Makoto Ishii (229384)
Naoki Hasegawa (1698301)
Osamu Iketani (4346008)
Sadatomo Tasaka (729727)
Shoji Suzuki (1424941)
Takahiro Asami (325491)
Takanori Asakura (3551786)
Tetsuro Kamo (4346002)
Tomoko Betsuyaku (87406)
Tomoyasu Nishimura (3551777)
Yohei Funatsu (4346005)
Yoshifumi Uwamino (4345999)
Yoshitake Yamada (3551792)
Publication date
Publisher
Doi

Abstract

Nebulizing time and speed, final remaining dose and the particle size in the compressor nebulizer. A digital weighing scale was used to measure the mean nebulizing speed and the final remaining dose. The particle sizes were measured using a Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, UK). (DOCX 186Â kb

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/52968...

Last time updated on 12/02/2018